November 15 - 16, 2018 - Philadelphia MA US
The materiality and complexity of gross-to-net continues to grow. For life science companies of all sizes and stages, proactive and strategic management of GTN is critical. CBI’s longstanding Gross-to-Net Summit is built for the learning needs and changing dynamics of pharmaceutical, biotech and generic drug companies. Whether your organization is pre-commercial revenue or is managing multiple products and large revenue streams, an understanding of GTN models and processes is paramount to success and compliance. Attendees consistently walk away with best practices for a well-designed, multi-faceted approach to GTN management for enhanced visibility, profitability and control.